This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Neovasc Inc. Announces Lemaitre Vascular Will Accelerate Its Acquisition Of Rights To In-House Manufacture Of Xenosure Product

Stocks in this article: NVC





TSX Venture Exchange: NVC

--Vascular Device Leader LeMaitre to Purchase Rights to Manufacture XenoSure Surgical Patch for US $4.6M--

--Neovasc will Continue to Supply Product During Transition and Will Redirect Freed-Up Manufacturing Capacity to Support Growing Sales to Transcatheter Heart Valve Customers--

--Proceeds from the Sale of Rights Will Help Fund Neovasc's Key Development Projects--

VANCOUVER, Oct. 2, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that it has amended its agreement with LeMaitre Vascular, Inc. (Nasdaq: LMAT) to allow LeMaitre to exercise its option to purchase certain specific rights to Neovasc's biological vascular surgical patch product technology on an accelerated basis, at an agreed price of US $4.6 million.

Under the terms of the original January 2009 agreement, LeMaitre Vascular had the option to purchase rights to certain specific uses of the technology from Neovasc on or after January 2, 2014, under a predetermined price mechanism. The new amendment allows LeMaitre to exercise its technology acquisition option 14 months early. LeMaitre has agreed to complete customary due diligence, and upon successful completion of this due diligence, the parties will close the transaction on or before October 31, 2012. Under the terms of the amended agreement, Neovasc will receive US $4.255 million on closing, with the balance payable one year later.

After the technology transfer, LeMaitre's right of use of the Neovasc biological vascular surgical patch technology will be limited to the manufacture of its XenoSure ® surgical patch product line, which is currently manufactured by Neovasc and distributed by LeMaitre. Neovasc will retain rights to all other applications of its biological tissue technologies. In addition to and concurrent with this amended agreement, the companies entered into a new supply agreement under which Neovasc will continue to supply the XenoSure product to LeMaitre while LeMaitre develops its own manufacturing capacity and obtains required regulatory approvals.

"This amended agreement with LeMaitre for the early purchase of rights to use our biological vascular surgical patch technology for manufacturing the XenoSure product is a good deal for both companies," said Alexei Marko, CEO of Neovasc. "The $4.6 million in proceeds from this transaction will enable us to continue aggressively advancing our two promising pipeline projects, without the need for additional financing in 2013. We look forward to presenting data on both our Tiara TM transcatheter mitral valve and our Reducer TM product for refractory angina at TCT 2012 later this month."

Mr. Marko continued, "The transfer of XenoSure patch manufacture to LeMaitre will allow Neovasc to continue to increase the focus of our biological products division on the supply of specialized tissue and manufacturing services to the transcatheter heart valve industry and other high margin applications. We anticipate that the capacity that is freed up as we wind down our production for LeMaitre will be absorbed by our increasing activities in these high growth areas, and we look forward to continued revenue growth in 2013."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs